Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Chief Business Officer | August 11, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 77,900 |
Reported balance
After 2026-08-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-11 · Purchase · Acquired 2,600 · Balance 77,900 F1: This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock, par value $0.0001 per share | 2,600 | $9.63 | $25,036.44 |
DisclosureSEC source: 0001193125-26-346966 · ownership.xml · nonDerivative · entry 1 Saxena Nishant C · CIK 0002136365 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,900 F1 · balance_after: This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported. Read SEC document |
| June 03, 2026 Filed Jun 3, 2026 21:36 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock, par value $0.0001 per share | 9,000 | $7.58 | $68,220.00 |
DisclosureSEC source: 0001193125-26-255834 · ownership.xml · nonDerivative · entry 2 Saxena Nishant C · CIK 0002136365 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,300 F2 · balance_after: This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 21:36 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock, par value $0.0001 per share | 4,500 | $7.33 | $32,998.50 |
DisclosureSEC source: 0001193125-26-255834 · ownership.xml · nonDerivative · entry 1 Saxena Nishant C · CIK 0002136365 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,300 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.33 to $7.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:51 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 192,300 | $0.00 Strike: $11.51 | $0.00 |
DisclosureSEC source: 0001193125-26-237103 · ownership.xml · derivative · entry 2 Saxena Nishant C · CIK 0002136365 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,300 Underlying: Common Stock · 192,300 shares Expires 2036-05-21 F3 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on May 21, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on June 21, 2027. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:51 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 58,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237103 · ownership.xml · nonDerivative · entry 1 Saxena Nishant C · CIK 0002136365 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,800 F1 · shares: On May 21, 2026, the Reporting Person was granted 58,300 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on May 21, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service. F2 · balance_after: This amount includes 58,300 unvested RSUs granted on May 21, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.